Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 5Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 2313Glioblastoma 2016Glioma 1402Central Nervous System Neoplasms 692Astrocytoma 668Neuroblastoma 647Gliosarcoma 480Oligodendroglioma 405Neoplasms 405Breast Neoplasms 327Medulloblastoma 307Carcinoma, Non-Small-Cell Lung 256Meningioma 229Recurrence 224Sarcoma 215Melanoma 207Neoplasm Metastasis 202Ependymoma 200Lung Neoplasms 199Neurofibromatosis 1 169Lymphoma 162Meningeal Carcinomatosis 138Osteosarcoma 135Ovarian Neoplasms 132Wilms Tumor 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Head and Neck Neoplasms 117Lymphoma, Non-Hodgkin 116Diffuse Intrinsic Pontine Glioma 113Rhabdomyosarcoma 107

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × CNS × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡